205 related articles for article (PubMed ID: 16268488)
1. Immediate type hypersensitivity after injection of nadroparin (Fraxiparin).
Bekkenk MW; van Zuuren EJ
Thromb Haemost; 2005 Sep; 94(3):673-4. PubMed ID: 16268488
[No Abstract] [Full Text] [Related]
2. Delayed hypersensitivity to heparin in a patient with cancer: fondaparinux may be safe but needs to be tested.
Colagiovanni A; Rizzi A; Buonomo A; De Pasquale T; Pecora V; Sabato V; Aruanno A; Pascolini L; Nucera E; Schiavino D
Contact Dermatitis; 2010 Aug; 63(2):107-8. PubMed ID: 20629676
[No Abstract] [Full Text] [Related]
3. Delayed allergic skin reactions to subcutaneous heparins. Tolerance of 2 recombinant hirudins.
Koch P; Reinhold S; Busch C
Contact Dermatitis; 2000 May; 42(5):278-9. PubMed ID: 10789845
[No Abstract] [Full Text] [Related]
4. Immediate type hypersensitivity to low molecular weight heparins and tolerance of unfractioned heparin and fondaparinux.
Harr T; Scherer K; Tsakiris DA; Bircher AJ
Allergy; 2006 Jun; 61(6):787-8. PubMed ID: 16677252
[No Abstract] [Full Text] [Related]
5. [Delayed hypersensitivity to heparins and heparinoids].
Nicolie B; Bonneau JC; Le Sellin J; Gay G; Leclere JM; Drouet M
Allerg Immunol (Paris); 2002 Feb; 34(2):47-50. PubMed ID: 11933754
[TBL] [Abstract][Full Text] [Related]
6. Compliance with platelet count monitoring recommendations and management of possible heparin-induced thrombocytopenia in hospitalized patients receiving low-molecular-weight heparin.
ten Berg MJ; van den Bemt PM; Huisman A; Schobben AF; Egberts TC; van Solinge WW
Ann Pharmacother; 2009 Sep; 43(9):1405-12. PubMed ID: 19690229
[TBL] [Abstract][Full Text] [Related]
7. [Determination of anti-Xa activity in cancer patients].
Somonova OV; Madzhuga AV; Elizarova AL; Zubrikhina GN
Klin Lab Diagn; 2008 Nov; (11):24, 33-4. PubMed ID: 19140408
[TBL] [Abstract][Full Text] [Related]
8. Acute generalized exanthematous pustulosis from dalteparin.
Komericki P; Grims R; Kränke B; Aberer W
J Am Acad Dermatol; 2007 Oct; 57(4):718-21. PubMed ID: 17610994
[TBL] [Abstract][Full Text] [Related]
9. Delayed hypersensitivity to enoxaparin.
Cabañas R; Caballero MT; López-Serrano MC; Díaz R; Contreras J; Barranco P; Moreno-Ancillo A
J Investig Allergol Clin Immunol; 1998; 8(6):383-4. PubMed ID: 10028487
[TBL] [Abstract][Full Text] [Related]
10. Eczema-like plaques to enoxaparin.
Valdés F; Vidal C; Fernández-Redondo V; Peteiro C; Toribio J
Allergy; 1998 Jun; 53(6):625-6. PubMed ID: 9689351
[No Abstract] [Full Text] [Related]
11. Intolerance of fondaparinux in a patient allergic to heparins.
Hirsch K; Ludwig RJ; Lindhoff-Last E; Kaufmann R; Boehncke WH
Contact Dermatitis; 2004 Jun; 50(6):383-4. PubMed ID: 15274739
[No Abstract] [Full Text] [Related]
12. Patch-test positivity in cutaneous reactions to enoxaparin.
Enrique E; Alijotas J; Cisteró A; san Miguel MM; Bartra J; Tresserra F
Contact Dermatitis; 2000 Jan; 42(1):43. PubMed ID: 10644025
[No Abstract] [Full Text] [Related]
13. Delayed-type hypersensitivity to the ultra-low-molecular-weight heparin fondaparinux.
Hohenstein E; Tsakiris D; Bircher AJ
Contact Dermatitis; 2004 Sep; 51(3):149-51. PubMed ID: 15479206
[No Abstract] [Full Text] [Related]
14. A fatal case of enoxaparin induced skin necrosis and thrombophilia.
Nadir Y; Mazor Y; Reuven B; Sarig G; Brenner B; Krivoy N
Eur J Haematol; 2006 Aug; 77(2):166-8. PubMed ID: 16856910
[TBL] [Abstract][Full Text] [Related]
15. [Cosmetics in allergy. Diagnosis and therapeutic choices].
Sánchez Palacios A
Allergol Immunopathol (Madr); 1994; 22(3):116-24. PubMed ID: 7976959
[No Abstract] [Full Text] [Related]
16. Iatrogenic calcinosis cutis following nadroparin injection.
Giorgini S; Martinelli C; Massi D; Lumini A; Mannucci M; Giglioli L
Int J Dermatol; 2005 Oct; 44(10):855-7. PubMed ID: 16207189
[TBL] [Abstract][Full Text] [Related]
17. Allergic reactions to enoxaparin and heparin: a case report and review of the literature.
Tiu A; Pang JM; Martin R; Officer N
N Z Med J; 2004 Oct; 117(1204):U1126. PubMed ID: 15505672
[No Abstract] [Full Text] [Related]
18. Delayed hypersensitivity skin reaction to enoxaparin.
Méndez J; de la Fuente R; Stolle R; Vega JM; Sanchís ME; Armentia A; Sánchez P; Fernández A
Allergy; 1996 Nov; 51(11):853-4. PubMed ID: 8947349
[No Abstract] [Full Text] [Related]
19. Differences in the safety profiles of two low-molecular-weight heparins.
Ofosu FA
Thromb Haemost; 2008 Jun; 99(6):989-90. PubMed ID: 18521496
[No Abstract] [Full Text] [Related]
20. Fondaparinux as an alternative therapy in heparin-induced delayed-type hypersensitivity skin lesions.
O'Meara AC; Demarmels Biasiutti F; Heizmann M
Thromb Haemost; 2007 Dec; 98(6):1389-91. PubMed ID: 18064346
[No Abstract] [Full Text] [Related]
[Next] [New Search]
